Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.66 |
| ▸ | LGALS9 | O00182 | 6/20 | 0.66 |
| ▸ | LGALS1 | P09382 | 6/20 | 0.66 |
| ▸ | LGALS7; LGALS7B | P47929 | 5/20 | 0.66 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.50 |
| ▸ | HK1 | P19367 | 2/20 | 0.48 |
| ▸ | HK2 | P52789 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9009735 | 1.00 | LGALS3 (0.66) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL11380069 | 1.00 | LGALS3 (0.66) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL30649267 | 1.00 | LGALS3 (0.66) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL8762532 | 1.00 | LGALS3 (0.66) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL15531572 | 1.00 | LGALS3 (0.66) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL13211174 | 0.91 | LGALS3 (0.70) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL26102195 | 0.91 | LGALS3 (0.70) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL12482435 | 0.90 | LGALS3 (0.76) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL10802114 | 0.90 | LGALS3 (0.64) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL7744292 | 0.88 | LGALS3 (0.61) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827663-B2 | Use of UAP inhibitors to inhibit flux through the hexosamine biosynthetic pathway | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827663-B2 | Use of UAP inhibitors to inhibit flux through the hexosamine biosynthetic pathway | UGDH, UMPS, UGGT1 | LGALS3 2745/4885LGALS9 2650/4885LGALS1 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.